Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.
Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.
复制标题
DOI：
10.3390/cancers13112830
复制
发表时间：
2021-06-06
期刊：
影响因子：
5.2
通讯作者：
Kim N
中科院分区：
文献类型：
--
作者：
Chu HH;Kim JH;Shim JH;Gwon DI;Ko HK;Shin JH;Ko GY;Yoon HK;Kim N
基线嗜中性粒细胞/淋巴细胞比值≥3是中期肝细胞癌化疗栓塞后总生存率的可靠独立预测因子，其预测值经交叉验证验证。嗜中性粒细胞与淋巴细胞比率（NLR）在预测肝细胞癌（HCC）患者经动脉化疗栓塞（TACE）治疗结局方面的临床影响尚不清楚，需要进行额外的大规模研究。这项回顾性研究评价了2008年至2017年期间接受TACE作为中期HCC一线治疗的初治患者的结局。在2013年之前和之后接受TACE的患者分别被分配到开发（n = 495）和验证（n = 436）队列。多变量考克斯分析确定了6个预测结局的因素，包括NLR，用于建立预测发展队列总生存期（OS）的模型。0-3、4-7和8-12的风险评分分别被定义为低风险、中等风险和高风险。在验证队列中，低、中和高风险组的中位OS时间分别为48.1、24.3和9.7个月（p < 0.001）。将预测OS的模型的时间依赖性ROC曲线应用于验证队列，显示3年和5年时的AUC值分别为0.72和0.70。多变量logistic回归分析发现，NLR ≥ 3是TACE后6个月疾病进展的显著预测因子（比值比，3.4; p < 0.001）。较高的基线NLR预测接受TACE治疗中期HCC的患者预后不良。
Baseline neutrophil-to-lymphocyte ratio ≥3 was a robust independent predictor of overall survival after chemoembolization for intermediate-stage hepatocellular carcinoma, with the predictive value verified by cross-validation. The clinical impact of neutrophil-to-lymphocyte ratio (NLR) in predicting outcomes in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) remain unclear, and additional large-scale studies are required. This retrospective study evaluated outcomes in treatment-naïve patients who received TACE as first-line treatment for intermediate-stage HCC between 2008 and 2017. Patients who underwent TACE before and after 2013 were assigned to the development (n = 495) and validation (n = 436) cohorts, respectively. Multivariable Cox analysis identified six factors predictive of outcome, including NLR, which were used to create models predictive of overall survival (OS) in the development cohort. Risk scores of 0–3, 4–7, and 8–12 were defined as low, intermediate, and high risk, respectively. Median OS times in the low-, medium-, and high-risk groups in the validation cohort were 48.1, 24.3, and 9.7 months, respectively (p < 0.001). Application to the validation cohort of time-dependent ROC curves for models predictive of OS showed AUC values of 0.72 and 0.70 at 3 and 5 years, respectively. Multivariable logistic regression analysis found that NLR ≥ 3 was a significant predictor (odds ratio, 3.4; p < 0.001) of disease progression 6 months after TACE. Higher baseline NLR was predictive of poor prognosis in patients who underwent TACE for intermediate-stage HCC.
登录
查看更多内容
影响因子：
3.7
作者：
Azab, Basem;Bhatt, Vijaya R.;Widmann, Warren D.
通讯作者：
Widmann, Warren D.
影响因子：
3.7
作者：
McNally, Megan E.;Martinez, Antonio;Schmidt, Carl R.
通讯作者：
Schmidt, Carl R.
影响因子：
13.5
作者：
Bruix, J;Llovet, JM
通讯作者：
Llovet, JM
影响因子：
6.7
作者：
Kim, Jin Hyoung;Shim, Ju Hyun;Park, Seong Ho
通讯作者：
Park, Seong Ho
巴塞罗那临床肝癌 B 期肝细胞癌患者的新亚期分类策略
影响因子：
4.1
作者：
Hu, Ke-Shu;Tang, Bei;Yin, Xin
通讯作者：
Yin, Xin